Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

In 2015, the Chinese Society of Hepatology and the Chinese Society of Gastroenterology published a consensus on primary ...

Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat ...

Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

Bile reflux gastritis (BRG) is a gastro-intestinal condition especially characterized by the reflux of bile into the stomach, further leading to mucosal inflammation along with various other clinical ...

GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there ...

Reduce the need for Cholecystectomy for gallstones after laparoscopic sleeve gastrectomy suggests a study published in the BMC Surgery.In this study, we aimed ...

The trials identified no serious adverse effects, and patients tolerated a daily dosage of 1500 mg for 24 weeks.